6 May 2016 - Two decades after its inception, the agency still fails to put patients’ interests first.

Fifteen years ago Garattini raised criticisms about the policy and attribution of the then young EMA and its Committee for Medicinal Products for Human Use (CHMP)

With the same aim of encouraging this institution to put the interests of patients and public health services first, he now offers an updated picture.

The current supervising directorate general of the European Commission is certainly more appropriate than before: first it was DG Enterprise, which also represents drug companies—a considerable conflict of interest. Today it is DG Sanco, which is responsible for health and consumers.

For more details, go to: http://www.bmj.com/content/353/bmj.i2412?etoc=